JonesTrading analyst Soumit Roy has maintained their bullish stance on DTIL stock, giving a Buy rating on May 15.
Soumit Roy has given his Buy rating due to a combination of factors related to Precision BioSciences’ robust pipeline and potential market impact. Roy’s optimism is partly anchored in the significant clinical milestones expected within the next 12 months for Precision BioSciences. These include the anticipated release of initial data from the iECURE study, targeting OTC deficiency treatment, and the presentation of clinical data from the company’s HBV program. The potential of these programs to validate Precision’s ARCUS genome editing technology is seen as a strong positive driver for the stock.
Furthermore, the financial health of Precision BioSciences, as indicated by the approximately $137 million in cash and equivalents, supports a solid cash runway into the second half of 2026, providing the company with ample resources to pursue its research and development goals. The Fast Track designation received from the FDA for one of its therapies further bolsters the company’s strategic positioning. Combined with a valuation analysis that includes DCF, NPV, and PE considerations, Roy’s $30 price target reflects confidence in the company’s technology value and the forthcoming clinical data that are expected to underpin the company’s growth trajectory.
In another report released on May 15, H.C. Wainwright also reiterated a Buy rating on the stock with a $60.00 price target.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Precision BioSciences (DTIL) Company Description:
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company’s propriety genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane in January 2006 and is headquartered in Durham, NC.
Read More on DTIL:
